High Expression of HLA-DQA1 Predicts Poor Outcome in Patients with Esophageal Squamous Cell Carcinoma in Northern China

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Mar 1

PMID 30813145

Citations 12

Authors

Fang-Fang Shen

Ying Pan

Jing-Zhong Li

Fang Zhao

Hai-Jun Yang

Jun-Kuo Li

Zhao-Wei Gao

Jing-Fen Su

Li-Juan Duan

Shu-Min Lun

Peng Zhang

Lin-Qiang Tian

Gang Sun

Da Huang

Yan-Tian Cao

Fu-You Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Our previous studies demonstrate that the major histocompatibility complex (MHC) is associated with the progression of esophageal squamous cell carcinoma (ESCC). HLA-DQA1, which belongs to the MHC Class II family, may be a potential biomarker in ESCC progression. However, the association between HLA-DQA1 and ESCC in high-incidence area of northern China has not been well characterized. The purpose of this study is to investigate the relationship of HLA-DQA1 expression with the progression and prognosis of ESCC.

Methods: We analyzed the expression profiles of HLA-DQA1 in esophageal cancer (EC) samples in the TCGA database and validated HLA-DQA1 expression by immunohistochemistry, western blotting, and quantitative reverse-transcription polymerase chain reaction in matched EC and normal tissues, respectively. The correlation between HLA-DQA1 expression and clinicopathologic characteristics of ESCC was further analyzed.

Result: Immunohistochemical analysis indicated that the expression level of HLA-DQA1 in ESCC tissues was significantly higher than the matched normal tissues (P < .001). HLA-DQA1 mRNA and protein expression were significantly higher in ESCC tissues compared to the matched normal tissues. Patients with family history negative or with tumor sizes >4 cm were associated with higher HLA-DQA1 expression levels. A prognostic significance of HLA-DQA1 was also found by the Log-rank method, in which high expression of HLA-DQA1 was correlated with a shorter overall survival time. The receiver operating characteristic (ROC) curve analysis yielded the area under the ROC curve value of 0.693. Univariate and multivariate analyses also suggest that high expression of HLA-DQA1 is a potential indicator for poor prognosis of ESCC.

Conclusions: Our results demonstrate that HLA-DQA1 plays an important role in ESCC progression and may be a biomarker for ESCC diagnosis and prognosis, as well as a potential target for the treatment of patients with ESCC.

Citing Articles

Using parenclitic networks on phaeochromocytoma and paraganglioma tumours provides novel insights on global DNA methylation.

Brempou D, Montibus B, Izatt L, Andoniadou C, Oakey R Sci Rep. 2024; 14(1):29958.

PMID: 39622952 PMC: 11612305. DOI: 10.1038/s41598-024-81486-9.

Importance of CD8 Tex cell-associated gene signatures in the prognosis and immunology of osteosarcoma.

Lu Y, Cao N, Zhao M, Zhang G, Zhang Q, Wang L Sci Rep. 2024; 14(1):9769.

PMID: 38684858 PMC: 11058769. DOI: 10.1038/s41598-024-60539-z.

Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning.

Zhao Y, Wei Y, Fan L, Nie Y, Li J, Zeng R Mol Med. 2023; 29(1):145.

PMID: 37884883 PMC: 10601311. DOI: 10.1186/s10020-023-00739-x.

HLA-DQA1 expression is associated with prognosis and predictable with radiomics in breast cancer.

Zhou J, Xie T, Shan H, Cheng G Radiat Oncol. 2023; 18(1):117.

PMID: 37434241 PMC: 10337141. DOI: 10.1186/s13014-023-02314-4.

Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death.

Lamberti M, Montico B, Ravo M, Nigro A, Giurato G, Iorio R Biomedicines. 2022; 10(8).

PMID: 36009442 PMC: 9405340. DOI: 10.3390/biomedicines10081896.

References

Nie Y, Yang G, Song Y, Zhao X, So C, Liao J . DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis. 2001; 22(10):1615-23. DOI: 10.1093/carcin/22.10.1615. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Jordanova E, Philippo K, Giphart M, Schuuring E, Kluin P . Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics. 2003; 55(4):203-9. DOI: 10.1007/s00251-003-0563-z. View

Liu Q, Hao C, Su P, Shi J . Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol. 2009; 44(8):960-9. DOI: 10.1080/00365520902998679. View

Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K . Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010; 15(2):126-34. DOI: 10.1007/s10147-010-0056-7. View

Li Y, Chen L, Nie C, Zeng T, Liu H, Mao X . Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. Cancer Res. 2011; 71(19):6106-15. DOI: 10.1158/0008-5472.CAN-10-4291. View

Zhang J, Tong Z, Yang L, Wang F, Chai H, Zhang F . PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer. 2012; 132(11):2567-77. DOI: 10.1002/ijc.27930. View

Moghbeli M, Abbaszadegan M, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A . Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol. 2013; 30(2):516. DOI: 10.1007/s12032-013-0516-9. View

Baccar A, Ferchichi I, Troudi W, Marrakchi R, Ben Hmida N, Jebini S . CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis. Dis Markers. 2013; 34(5):363-71. PMC: 3810233. DOI: 10.3233/DMA-130982. View

10.

Blom R, Lagarde S, van Oudenaarde K, Klinkenbijl J, Hulshof M, van Laarhoven H . Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013; 20(8):2693-8. DOI: 10.1245/s10434-013-2936-3. View

11.

Ge X, Ma H, Zheng X, Ruan H, Liao X, Xue W . HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci. 2013; 104(12):1675-82. PMC: 7653522. DOI: 10.1111/cas.12296. View

12.

Shen F, Yue W, Zhou F, Pan Y, Zhao X, Jin Y . Variations in the MHC region confer risk to esophageal squamous cell carcinoma on the subjects from high-incidence area in northern China. PLoS One. 2014; 9(3):e90438. PMC: 3942432. DOI: 10.1371/journal.pone.0090438. View

13.

Jiang Y, Li Q, Zhao J, Lv J . Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2014; 15(5):2309-12. DOI: 10.7314/apjcp.2014.15.5.2309. View

14.

Ekkirala C, Cappello P, Accolla R, Giovarelli M, Romero I, Garrido C . Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. Pancreas. 2014; 43(7):1066-72. DOI: 10.1097/MPA.0000000000000160. View

15.

Wu C, Wang Z, Song X, Feng X, Abnet C, He J . Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet. 2014; 46(9):1001-1006. PMC: 4212832. DOI: 10.1038/ng.3064. View

16.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

17.

Angell T, Lechner M, Jang J, LoPresti J, Epstein A . MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014; 20(23):6034-44. PMC: 4252612. DOI: 10.1158/1078-0432.CCR-14-0879. View

18.

Hu J, Li L, Chen Y, Liu C, Cui X, Yin L . HLA-DRB1 and HLA-DQB1 methylation changes promote the occurrence and progression of Kazakh ESCC. Epigenetics. 2014; 9(10):1366-73. PMC: 4623353. DOI: 10.4161/15592294.2014.969625. View

19.

Haworth K, Leddon J, Chen C, Horwitz E, Mackall C, Cripe T . Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer. 2014; 62(4):571-6. PMC: 4339346. DOI: 10.1002/pbc.25359. View

20.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View